Jeng-Pyng Shaw
Overview
Explore the profile of Jeng-Pyng Shaw including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
320
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
McKinnell R, Armstrong S, Beattie D, Fatheree P, Long D, Marquess D, et al.
Bioorg Med Chem Lett
. 2013 Jun;
23(14):4210-5.
PMID: 23756062
The discovery of a series of 5-HT4 receptor agonists based on a novel 2-alkylbenzimidazole aromatic core is described. Optimization of the 2-substituent of the benzimidazole ring led to a series...
2.
Long D, Frieman B, Hegde S, Hill C, Jiang L, Kintz S, et al.
Bioorg Med Chem Lett
. 2013 Jan;
23(4):939-43.
PMID: 23317571
Lowering of intra-ocular pressure is the primary pharmacologic approach for the treatment of glaucoma and a number of distinct mechanisms of action have been clinically validated. Targeting of multiple mechanisms...
3.
Long D, Armstrong S, Beattie D, Choi S, Fatheree P, Gendron R, et al.
Bioorg Med Chem Lett
. 2012 Sep;
22(19):6048-52.
PMID: 22959244
Utilization of Theravance's multivalent approach to drug discovery towards 5-HT(4) receptor agonists with a focus on identification of neutral (non-charged at physiological pH) secondary binding groups is described. Optimization of...
4.
Long D, Armstrong S, Beattie D, Choi S, Fatheree P, Gendron R, et al.
Bioorg Med Chem Lett
. 2012 Jun;
22(14):4849-53.
PMID: 22683222
Further application of our multivalent approach to drug discovery directed to 5-HT(4) receptor agonists is described. Optimization of the linker and secondary binding amine in the indazole-tropane primary binding group...
5.
Samara E, Shaw J, Barriere S, Wong S, Worboys P
Antimicrob Agents Chemother
. 2012 Jan;
56(4):2067-73.
PMID: 22252798
A population pharmacokinetic model of telavancin, a lipoglycopeptide antibiotic, was developed and used to identify sources of interindividual variability. Data were obtained from healthy subjects (seven phase 1 studies), patients...
6.
Hegde S, Okusanya O, Skinner R, Shaw J, Obedencio G, Ambrose P, et al.
Antimicrob Agents Chemother
. 2011 Dec;
56(3):1578-83.
PMID: 22155835
TD-1792 is a novel glycopeptide-cephalosporin heterodimer investigational antibiotic that displays potent bactericidal effects against clinically relevant Gram-positive organisms in vitro. The present studies evaluated the in vivo pharmacokinetics (PK) and...
7.
Identification of a putative regulator of early T cell activation genes. Science. 1988. 241: 202-205
Shaw J, Utz P, Durand D, Toole J, Emmel E, Crabtree G
J Immunol
. 2010 Oct;
185(9):4972-5.
PMID: 20962265
No abstract available.
8.
Shaw J, Jaw-Tsai S
Xenobiotica
. 2010 Oct;
41(1):82-9.
PMID: 20946087
Telavancin is an intravenous lipoglycopeptide antibiotic active against many Gram-positive pathogens via inhibition of bacterial cell wall synthesis and disruption of bacterial membrane function. Non-compartmental pharmacokinetic parameters of telavancin (clearance...
9.
Goldberg M, Wong S, Shaw J, Kitt M, Barriere S
Pharmacotherapy
. 2010 Jul;
30(8):806-11.
PMID: 20653356
Study Objective: To assess the safety and tolerability, and the effect of sex on the pharmacokinetic disposition, of a single intravenous dose of telavancin 10 mg/kg in elderly (> or...
10.
Shaw J, Cheong J, Goldberg M, Kitt M
Antimicrob Agents Chemother
. 2010 Jun;
54(8):3365-71.
PMID: 20516282
The mass balance and pharmacokinetics of telavancin, a semisynthetic lipoglycopeptide antimicrobial agent, were characterized in an open-label, phase 1 study of six healthy male subjects. After a single 1-h intravenous...